What have been the most significant challenges this year, and what are the solutions?

Key challenges include economic and currency fluctuations, procurement difficulties, energy and logistics costs, and foreign trade restrictions. Our solution is not reactive; it is based on increasing supply chain resilience, diversifying product portfolios and markets, strengthening R&D, and precisely managing costs and working capital. The more complete our domestic production chain, the less vulnerable we become to external shocks.

Our main differentiator is a combination of three advantages: depth of the value chain, product diversity, and technical/R&D capabilities. We are more than just a product supplier; we aim to provide reliable solutions for the entire supply chain, from basic chemicals to Active Pharmaceutical Ingredients (APIs). Our three decades of experience and development of strategic products like Acetaminophen, Metronidazole, and Metformin allow us to play an active role in responding to customer needs.

Our approach is development combined with resilience. Completing the “Petrochemical to Pharmaceutical” value chain, localizing strategic APIs and raw materials, increasing product capacity, and strengthening collaborations with pharmaceutical companies are our top priorities. We are committed to turning the country’s production capacity into a sustainable competitive advantage.